AUSTIN â Texans age 50 and older will be eligible to receive the Covid-19 vaccine beginning March 15, state health officials announced Wednesday.
âExpanding to ages 50 to 64 will continue the stateâs priorities of protecting those at the greatest risk of severe outcomes and preserving the stateâs health care system,â said Imelda Garcia, Department of State Health Services associate commissioner for laboratory and infectious disease services and chair of the Expert Vaccine Allocation Panel.
The move to expand eligibility to a new category of Texans â labeled 1C â means that vaccine availability is ramping up across the state. However, appointments may continue to be hard to find, as the number of eligible recipients outnumbers the vaccine supply. Before the Wednesday announcement, between 10 million and 13 million people â more than one-third of Texasâ population â were already eligible, according to state health officials.
Quinnipiac: Vaccinated students still need to be tested
FacebookTwitterEmail
1of3
Syringes filled with COVID-19 vaccine wait on a table at Hartford HealthCare’s new mass vaccination clinic on the west campus of Sacred Heart University, in Fairfield, Conn. March 10, 2021.Ned Gerard / Hearst Connecticut MediaShow MoreShow Less
2of3
Gina Kelly fills a syringe with COVID-19 vaccine at Hartford HealthCare’s new mass vaccination clinic on the west campus of Sacred Heart University, in Fairfield, Conn. March 10, 2021.Ned Gerard / Hearst Connecticut MediaShow MoreShow Less
3of3
HAMDEN As more and more people get vaccinated against COVID-19 in Connecticut, the list of what people can and can’t do once they’ve received their shots has sometimes been murky.
Experts: Too soon to know if COVID-19 vaccine booster needed
FacebookTwitterEmail
(FILES) In this file photo RN Valerie Massaro administers the second dose of the Pfizer/BioNTech vaccine to health care workers, Twenty-one days after they received their first shot from Hartford HealthCare at the Hartford Convention Center in Hartford, Connecticut on January 4, 2021. - Sales of the Covid-19 vaccine developed by Pfizer and BioNTech could reach up to $15 billion in 2021 and go higher if Pfizer signs additional supply contracts, Pfizer said on February 2, 2021. The projections came as Pfizer reported fourth-quarter and full-year profits and released forecasts for 2021. Pfizer projected full-year 2021 sales of between $44.4 to $46.4 billion, excluding sales for the Covid-19 vaccine. (Photo by Joseph Prezioso / AFP) (Photo by JOSEPH PREZIOSO/AFP via Getty Images)JOSEPH PREZIOSO / AFP via Getty Images